Randomized Trialhigh evidence

Efficacy and Safety of Ulinastatin in the Treatment of Patients with Sepsis: The ADJUST Trial.

Chest·November 6, 2026·PMID 42994751

Why it matters

Sepsis remains a leading cause of ICU mortality, and prior observational data suggested ulinastatin might improve survival. This adequately powered RCT provides high-level evidence that adjunctive ulinastatin does not reduce mortality and may increase adverse events, informing critical care and internal medicine practice.

Infographic summary of Efficacy and Safety of Ulinastatin in the Treatment of Patients with Sepsis: The ADJUST Trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled